Far fewer cases of breast and five other cancers are being diagnosed during the COVID-19 pandemic.
Delaying breast cancer surgery for people diagnosed with DCIS or early-stage estrogen-receptor-positive invasive disease doesn't seem to affect survival.
Starting screening mammograms at age 40 instead of age 50 saves women's lives.
The early weeks of the COVID-19 pandemic caused 44% of breast cancer survivors to have a delay in care, according to an online survey.
A single dose of radiation therapy given during lumpectomy surgery offered about the same outcomes for early-stage breast cancer as traditional whole-breast radiation therapy given after surgery.
Recommendations from a European Society for Medical Oncology expert panel say doctors should not stop or delay any type of cancer treatment that might affect a person's overall survival and that all people diagnosed with cancer are not automatically at high risk for serious complications if they do get COVID-19.
Expanded Medicaid coverage through the Affordable Care Act didn't seem to reduce the disparity in breast cancer death rates between Black and white women.
Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.
When treating locally advanced or metastatic triple-negative breast cancer for the first time, adding Tecentriq to Taxol did not improve survival, while adding Tecentriq to Abraxane did improve survival.
A small study found that women who had textured implants for reconstruction after breast cancer surgery had a small but statistically significant increase in the risk of the breast cancer coming back.
Postmenopausal women and men diagnosed with advanced-stage hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation lived about 8 months longer when treated with the combination of the targeted therapy Piqray and the hormonal therapy Faslodex compared to Faslodex alone.
Adding Tecentriq to chemotherapy before surgery for early-stage triple-negative breast cancer offered higher pathologic complete response rates than chemotherapy alone, no matter the PD-L1 status of the cancer.
Women diagnosed with childhood or young adult cancer treated with radiation therapy who developed breast cancer before menopause were more likely to die from breast cancer compared to similar women who didn't have childhood or young adult cancer.
People diagnosed with metastatic HER2-negative breast cancer with a BRCA1 or BRCA2 mutation treated with experimental veliparib and chemotherapy lived about 2 months longer without the cancer growing if they continued on veliparib after stopping chemotherapy.
Adding Ibrance to Faslodex as a first treatment for advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that either came back (recurred) more than 1 year after completing 5 or more years of hormonal therapy or was metastatic at first diagnosis improved progression-free survival compared to Faslodex alone.
Breast cancers found in between regular screening mammograms (called interval cancers by doctors) were more likely to have aggressive characteristics, and women diagnosed with them were more likely to die from breast cancer compared to breast cancers found by routine screening.
After whole-breast radiation, a boost dose to the area where the tumor was further reduced the risk of moderate- or high-grade DCIS coming back.
Mindfulness meditation seems to ease pain by allowing people to separate pain from things they’re experiencing.
Compared with doctors’ choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.
On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer.
On Nov. 13, 2020, the FDA approved the immunotherapy Keytruda in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.
Women with type 2 diabetes who take metformin to control their blood sugar appear to have a lower risk of estrogen-receptor-positive breast cancer.
The first screening mammography guidelines for breast cancer survivors age 75 and older encourage people and their doctors to come to a decision that is individualized for each person after discussing the benefits and risk of screening mammograms, as well as the person's preferences.
A study offers a first peek at the biology behind scalp cooling by finding that scalp cooling dramatically reduces the amount of chemotherapy medicine absorbed by the hair follicles.